Safety and short-term effectiveness of endoscopic sleeve gastroplasty using overstitch: preliminary report from a multic
- PDF / 1,079,223 Bytes
- 7 Pages / 595.276 x 790.866 pts Page_size
- 86 Downloads / 166 Views
and Other Interventional Techniques
Safety and short‑term effectiveness of endoscopic sleeve gastroplasty using overstitch: preliminary report from a multicenter study Manoel Galvao Neto1 · Rena C. Moon2 · Luiz Gustavo de Quadros1 · Eduardo Grecco1 · Admar Concon Filho1 · Thiago Ferreira de Souza1 · Luis Augusto Mattar3 · Jose Americo Gomides de Sousa3 · Barham K. Abu Dayyeh4 · Helmut Morais5 · Felipe Matz6 · Muhammad A. Jawad2 · Andre F. Teixeira2 Received: 14 June 2019 / Accepted: 9 October 2019 © Springer Science+Business Media, LLC, part of Springer Nature 2019
Abstract Background Endoscopic sleeve gastroplasty (ESG) is an option for patients with Class I and II obesity or patients who refuse to undergo a laparoscopic bariatric surgery. The aims of this study are as follows: (1) to demonstrate a short-term outcome after primary ESG and (2) to compare the effectiveness of weight loss between Class I and Class II obesity patients. Methods Patients undergoing ESG at four bariatric centers in Brazil between April 1, 2017 and December 31, 2018 were prospectively enrolled in the study (BMI 30.0–39.9 kg/m2). ESG was performed using Overstitch (Apollo Endosurgery, Austin, TX). Descriptive analysis, t test, Chi-square test, and Mann–Whitney test were used to present the results. Results A total of 233 patients underwent primary ESG. The mean age and BMI of the patients were 41.1 years and 34.7 kg/ m2, respectively. Following ESG, the mean percentage of total weight loss (TWL) was 17.1% at 6 months and 19.7% at 12 months. Percentage of excess BMI loss (EBMIL) was 47.3% at 6 months and 54.8% at 12 months after ESG. The mean EBMIL was significantly greater among patients with Class I obesity than those with Class II obesity at 6 (51.1% vs. 43.7%) and 12 months (60.2% vs. 49.2%). One patient experienced bleeding during the procedure that was managed with sclerotherapy. Conclusion Short-term results suggest that ESG is a safe and effective option for patients with Class I and II obesity. Keywords Endoscopic · Sleeve gastroplasty · Weight loss · Safety · Effectiveness The prevalence of obesity is increasing worldwide and poses a serious public health concern [1]. Obesity is associated with a higher risk of developing diabetes mellitus, hypertension, and various types of cancers [1]. For severe obesity [body mass index (BMI) ≥ 35 kg/m2], bariatric surgery is known to be effective for sustained significant weight loss * Andre F. Teixeira [email protected] 1
ABC Medical School, Sao Paulo, Brazil
2
Department of Bariatric Surgery, Orlando Regional Medical Center, Orlando Health, 89 W Copeland Dr, 1st Floor, Orlando, FL, USA
3
LEV Advanced Obesity Treatment Center, Uberlandia, Minas Gerais, Brazil
4
Mayo Clinic, Rochester, MN, USA
5
Hospital Geral de Fortaleza, Fortaleza, Ceara, Brazil
6
Endodiagnostic, Rio de Janeiro, Brazil
[2]. Bariatric procedures, such as laparoscopic sleeve gastrectomy (LSG), are also effective for patients with Class I obesity (BMI less than 35 kg/m2). However, fo
Data Loading...
